Overview
Semax is a synthetic heptapeptide derived from the 4-7 fragment of ACTH (adrenocorticotropic hormone) - specifically ACTH(4-7), extended with the Pro-Gly-Pro C-terminal tripeptide sequence to resist enzymatic degradation and improve CNS penetration. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s-90s and has been registered in Russia for the treatment of stroke, brain ischemia, and cognitive impairment.
Unlike its parent molecule ACTH, Semax has no corticosteroid-releasing activity (no adrenocortical stimulation), making it pharmacologically selective for CNS effects.
Semax is considered one of the most potent cognitive enhancers in the peptide nootropic category, with a profile encompassing neuroprotection, enhanced attention, memory, and stress adaptation - without stimulant side effects or dependence.
Mechanism of Action
BDNF and NGF Upregulation: Semax significantly increases expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in hippocampal tissue. BDNF is critical for synaptic plasticity, long-term potentiation, and neurogenesis - the molecular basis of learning and memory.
Dopaminergic Modulation: Semax modulates dopamine receptor expression and enhances dopaminergic transmission in prefrontal cortex, contributing to improved working memory, attention, and motivation.
Serotonin System: Upregulates serotonin receptor expression in limbic structures - relevant to mood, anxiety, and stress resilience effects.
Nitric Oxide (NO) Modulation: Regulates NO synthase activity, improving cerebral blood flow in ischemic conditions - the primary mechanism behind its stroke and ischemia applications.
Neuroprotection: Reduces oxidative stress, excitotoxicity (glutamate-mediated), and inflammatory cytokine production in neurons. Robust neuroprotective signal in stroke models.
Clinical Research & Evidence
Evidence Level: EL3 - Russian clinical data for stroke; limited Western research
| Study | N | Focus | Finding |
|---|---|---|---|
| Gusev et al. 2000 | 60 | Ischemic stroke | Improved neurological outcomes vs. standard care |
| Lebedeva et al. 2008 | 100 | Cognitive impairment | Improved memory and attention |
| Shevchenko et al. 2012 | 70 | Optic nerve atrophy | Improved visual acuity |
Russian registration: Registered in Russia for ischemic stroke and cognitive impairment - the most clinically developed Western-equivalent use case in the Russian regulatory system.
Research-Referenced Dosing Protocols
Intranasal (most common):
- 300-900 mcg per dose
- 1-3x daily in divided doses
- Morning dosing preferred (dopaminergic stimulation may interfere with sleep if dosed late)
N-Acetyl Semax: A modified version with an acetyl group added at the N-terminus - reported to be more potent and longer-lasting; doses typically 300-600 mcg intranasal.
Side Effects & Contraindications
Reported:
- Nasal irritation or dryness
- Increased irritability or anxiety at high doses
- Transient headache
- Sleep disturbance if dosed late in the day
Generally well-tolerated in Russian clinical studies with no reported severe adverse events at standard doses.
Contraindications:
- Anxiety disorders or psychosis - dopaminergic stimulation may exacerbate
- Pregnancy
- Concurrent psychostimulant use (additive effects)
Legal & Regulatory Status
| Region | Status |
|---|---|
| Russia | Registered medication (prescription for stroke, OTC sold as nootropic in some forms) |
| United States | Not FDA approved; research chemical |
| European Union | Not EMA approved |
Research Citations
- Gusev EI, et al. Results of clinical trials of Semax in the treatment of patients at the early stages of ischemic stroke. Zh Nevrol Psikhiatr Im SS Korsakova. 2000.
- Lebedeva IS, et al. Effects of Semax on the brain biopotentials in humans. Bull Exp Biol Med. 2008.
- Shevchenko LA, et al. Use of Semax in optic nerve atrophy. Vestn Oftalmol. 2012.
- Eremin KO, et al. Semax, an analog of ACTH 4-7, affects functional activity of brain dopaminergic systems. Bull Exp Biol Med. 2005.